Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis-Reference-Cited by-同舟云学术

Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis

Published:2015-04-22 Issue:5 Volume:79 Page:789-800
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Gupta Neeraj¹,Zhao Yuan¹,Hui Ai-Min²,Esseltine Dixie-Lee²,Venkatakrishnan Karthik¹

Affiliation:

1. Clinical Pharmacology; Takeda Pharmaceuticals International Co; Cambridge MA USA

2. Oncology Clinical Research; Takeda Pharmaceuticals International Co; Cambridge MA USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.12542/fullpdf

Reference45 articles.

1. Proteasome inhibitors in multiple myeloma: 10 years later;Moreau;Blood,2012

2. Millennium: The Takeda Oncology Company VELCADE® (bortezomib) for injection. Prescribing information 2013 http://www.velcade.com/files/PDFs/VELCADE_PRESCRIBING_INFORMATION.pdf

3. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study;Moreau;Lancet Oncol,2011

4. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma;Richardson;N Engl J Med,2005

5. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma;San Miguel;N Engl J Med,2008

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Opportunity Strikes for Reducing Cancer Drug Waste: Bortezomib as an Example of Vial Mis-Sizing in Oncology;JCO Oncology Practice;2023-11-13

2. A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development;Journal of Pharmacokinetics and Pharmacodynamics;2023-03-04

3. Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE‐MM1 study in multiple myeloma patients;CPT: Pharmacometrics & Systems Pharmacology;2022-06-13

4. Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial;BMJ Open;2022-06

5. Pharmacokinetic aspects of the clinically used proteasome inhibitor drugs and efforts toward nanoparticulate delivery systems;Journal of Pharmaceutical Investigation;2021-05-08